Arthrex Again? Federal Circuit Says, “No More!” -
In Cywee Group Ltd. v. Google LLC, Appeal No. 20-1565, the Federal Circuit held that, while the Appointments Clause requires that the USPTO Director have the power to...more
Inventor’s Testimony Regarding Actual Reduction to Practice Was Sufficiently Corroborated In Dionex Softron GmbH v. Agilent Technologies, Inc., Appeal No. 21-2372, the Federal Circuit held that the PTAB did not err in...more
Collateral Estoppel Is Applicable in IPRs When the Question of Patentability Is the Same -
In Google LLC v. Hammond Development International, Inc. Appeal No. 21-2218, the Federal Circuit held that Google filed an IPR on...more
Restrictive Definitions Incorporated by Reference Do Not Necessarily Control for Later Patents in the Same Family -
In Finjan LLC v. Eset, LLC, Appeal No. 21-2093, the Federal Circuit held that specific definitions...more
Avoiding § 101 Eligibility Issues in Internet-Centric Method Claims -
In Weisner v. Google LLC, Appeal No. 21-2228, the Federal Circuit held that the specific implementation of an abstract idea, such as improving Internet...more
Duplicative-Litigation Doctrine: Proper Motion Practice is Essential to Avoid Dismissal of Duplicative Complaints -
In Arendi S.A.R.L. v. LG Electronics Inc., Appeal No. 21-1967, the Federal Circuit held that under the...more
In Thaler v. Vidal, Appeal No. 21-2347, the Federal Circuit held that, under the Patent Act, an “inventor” must be a natural person. Therefore, an AI system cannot be an inventor. ...more
In LG Electronics Inc. v. Immervision Inc., Appeal No. 21-2037, the Federal Circuit held that, where a reference contains an “obvious” error in a disclosure, even one not immediately apparent from the face of the disclosure,...more
Claims With Clerical Errors Can Be Judicially Corrected and Willfully Infringed -
In Pavo Solutions LLC v. Kingston Technology Company, Inc., Appeal No. 21-1834, the Federal Circuit held that a court can correct obvious...more
Somebody’s Wrong: PTAB Must Resolve Conflicting Factual Testimony During IPR -
In Google LLC v. IPA Technologies Inc., Appeal No. 21-1179, the Federal Circuit held that, for purposes of determining whether a reference was...more
6/20/2022
/ Appointments Clause ,
Arthrex Inc v Smith & Nephew Inc ,
Claim Construction ,
Constitutional Challenges ,
Federal Vacancies Reform Act ,
Google ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents
A Construction That Eliminates the Entire Scope of Dependent Claims Should Be Avoided -
Littelfuse, Inc. v. Mersen USA Ep Corp., Appeal No. 21-2013, the Federal Circuit vacated a claim construction that violated the doctrine...more
Claim Limitation Not Disclosed by Any Reference but Disclosed by “Proposed Combination” of References Is Obvious -
In Hoyt Augustus Fleming v. Cirrus Design Corporation, Appeal No. 21-1561, the Federal Circuit held that a...more
4/5/2022
/ Anticipation ,
Claim Construction ,
Claim Limitations ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Motion to Amend ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Sua Sponte ,
Substitute Claims
Ordered To Agree: Binding Settlement Agreement Provision Found Despite Absence of Singular, Executed Agreement -
In Plasmacam, Inc. v. Cncelectronics, LLC Appeal No. 21-1689, the Federal Circuit held that an agreement on...more
3/22/2022
/ Appeals ,
Binding Agreements ,
Broadest Reasonable Interpretation Standard ,
Claim Construction ,
Contract Terms ,
Estoppel ,
Inter Partes Review (IPR) Proceeding ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Preliminary Injunctions ,
Prior Art ,
Settlement Agreements
避而不谈可能支持否定性权利要求限定 -
在 Novartis Pharmaceuticals 诉 Accord Healthcare Inc. 一案（上诉案件编号：21- 1070）中，联邦巡回上诉法院认为，一项对药物“速效剂量”避而不谈的专利申请，为要求不存在此类剂量的否定 性权利要求限制提供了书面说明支持。
...more
2/10/2022
/ Claim Construction ,
Indefiniteness ,
Intellectual Property Protection ,
Novartis ,
Patent Applications ,
Patent Examinations ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
記述がないことがクレームの否定的限定のサポートと解釈できる場合がある
Federal Circuit は、Novartis Pharmaceuticals v. Accord Healthcare Inc. (Appeal No. 21-1070) に おいて、薬剤の「初回負荷用量」についての記述がない特許出願は、そのような用量がないことを要 求するクレームの否定的限定に記述によるサポートを提供していることになると判示した。
...more
2/10/2022
/ Claim Construction ,
Indefiniteness ,
Intellectual Property Protection ,
Novartis ,
Patent Applications ,
Patent Examinations ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
January 2022 Federal Circuit Newsletter (Japanese) January 2022 Federal Circuit Newsletter (Chinese) Silence May Support Negative Claim Limitation In Novartis Pharmaceuticals v. Accord Healthcare Inc. Appeal No. 21-1070, the...more
2/9/2022
/ Claim Construction ,
Indefiniteness ,
Intellectual Property Protection ,
Novartis ,
Patent Applications ,
Patent Examinations ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
Ranges for Interdependent and Interactive Components Can Be Tricky to Derive -
In Modernatx, Inc. v. Arbutus Biopharma Corporation, Appeal No. 20-2329, the Federal Circuit held that a presumption of obviousness based on...more
1/11/2022
/ AstraZeneca ,
Generic Drugs ,
Instrinsic Evidence ,
Intel ,
Inter Partes Review (IPR) Proceeding ,
Moderna Inc. ,
Mylan Pharmaceuticals ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Prior Art ,
Qualcomm
Venue and Pleading Infringement in Hatch-Waxman Litigation Turn on Location and Identity of ANDA Filer -
In Celgene Corp. v. Mylan Pharm. et al., Appeal No. 21-1154, the Federal Circuit held that in Hatch-Waxman...more
12/9/2021
/ Abbreviated New Drug Application (ANDA) ,
Apple ,
Article III ,
Biogen Idec ,
Dr. Reddy’s Labs. ,
Generic Drugs ,
Hatch-Waxman ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Mylan Pharmaceuticals ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Qualcomm ,
Standing ,
Written Descriptions
No Assembly, No Infringement – Federal Circuit Declines to Expand the “Final Assembler” Theory of Direct Infringement
In Acceleration Bay LLC v. Take-Two Interactive Software, Appeal No. 20-1700 the Federal Circuit held that...more
11/9/2021
/ Abstract Ideas ,
CLS Bank v Alice Corp ,
Computer-Related Inventions ,
Direct Infringement ,
Gaming ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Software
Arguments to the Patent Office That Contradict Information Submitted to the FDA Support an Inference of Deceptive Intent
In Belcher Pharmaceuticals v. Hospira, Inc., Appeal No. 20-1799, the Federal Circuit held that a...more
10/6/2021
/ Deceptive Intent ,
Evidence ,
Failure To Disclose ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Hatch-Waxman ,
Hospira ,
Inequitable Conduct ,
Intellectual Property Protection ,
Motion to Transfer ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patent Prosecution ,
Patents ,
Pharmaceutical Patents ,
Post-Grant Review ,
Prior Art ,
USPTO ,
Venue
It’s No Secret That a Related Company’s Physical Presence in a Jurisdiction May Not Be Enough For Proper Venue -
In Andra Group, LP v. Victoria’s Secret Stores, LLC, Appeal No. 20-2009, The Federal Circuit held that an...more
9/20/2021
/ Abstract Ideas ,
Eli Lilly ,
Improper Venue ,
Inter Partes Review (IPR) Proceeding ,
Jurisdiction ,
Nexus ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Physical Presence Test ,
Preamble ,
Principal Place of Business ,
Retailers ,
Teva Pharmaceuticals ,
Victoria Secret
District Court’s Pleading Standard Returns an Error Code in PS4 Battle -
In Bot M8 LLC v. Sony Corporation Of America, Appeal No. 20-2218, the Federal Circuit held that the district court’s view that infringement...more
8/18/2021
/ Amended Complaints ,
Claim Construction ,
Failure To State A Claim ,
Gaming ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pleading Standards ,
Prior Art ,
Qualcomm ,
Sony ,
Sua Sponte
Bulk-Filed Patent Applications Claiming Distant Priority Trigger Prosecution Laches -
In Hyatt v. Hirshfeld, Appeal No. 18-2390, the Federal Circuit held that the PTO met its burden to prove prosecution laches for bulk-filed...more
7/28/2021
/ Amazon Marketplace ,
Antitrust Provisions ,
Apple ,
Assignor Estoppel ,
Claim Construction ,
Compensation ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inventions ,
Laches ,
NCAA ,
Patent Applications ,
Patent Infringement ,
Patents ,
Prior Art ,
Standalone Authority ,
Subject Matter Jurisdiction ,
USPTO ,
Venue
Court Grants Relief From Judgment After Witness Lies About the Bed of Its Own Making -
In Cap Export, LLC v. Zinus, Inc., Appeal No. 20-2087, the Federal Circuit held that a judgment and injunction were properly set aside...more
6/25/2021
/ Abstract Ideas ,
Federal Rules of Civil Procedure ,
Inventions ,
Inventors ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Personal Jurisdiction ,
Section 101 ,
Set-Asides ,
Witness Statements
Copying From a Copyrighted Computer Program May Be Fair Use to the Extent Needed to Promote Adoption of the Use of Accrued Talents in Creating a New Software Platform -
In Google LLC v. Oracle America, Inc., Appeal No....more
5/28/2021
/ Admissible Evidence ,
Copyright ,
Copyright Infringement ,
Fair Use ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Oracle v Google ,
Patent Royalties ,
Prior Art ,
SCOTUS ,
Software Developers ,
Source Code ,
Transformative Use